WASHINGTON (RTW) — The endorsement of leucovorin, a derivative of vitamin B, by the Trump administration as a treatment for autism has revealed a rift between government objectives and the scientific community’s standpoint.
Dr. Richard Frye, a child neurologist from Arizona who played a role in proposing the drug’s use, expressed surprise at the swift approval, stating, “We anticipated more studies were necessary before any endorsement.”
Critics of the policy assert that the evidence supporting leucovorin is largely inconclusive and comes from small studies lacking credible validation. “We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms,” said Dr. David Mandell, a psychiatry professor.
Despite this, there is a burgeoning interest among parents regarding the drug. Some have reported positive changes in their children's behavior following its use, further complicating the conversation about its safety and efficacy.
While researchers have underscored the necessity of extensive trials, the administration's acceleration of the drug's use could lead to a broader acceptance among healthcare providers before substantial proof of safety emerges.
Amidst this unfolding scenario, the therapeutic claims surrounding leucovorin need cautious handling as past experimental treatments have often resulted in setbacks once subjected to rigorous evaluations. Experts voice concern that jumping ahead could not only undermine trust but also endanger vulnerable patients.
